# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activit...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-ex...
HC Wainwright & Co. analyst Emily Bodnar maintains MiNK Therapeutics (NASDAQ:INKT) with a Buy and lowers the price targe...
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $...
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and co...